FRM
TARS icon

Fox Run Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Fox Run Management’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$504K Buy
8,004
+3,317
+71% +$212K 0.08% 471
2026
Q1 		$314K Sell
4,687
-6,916
-60% -$483K 0.05% 611
2025
Q4 		$950K Buy
11,603
+3,166
+38% +$236K 0.15% 232
2025
Q3 		$501K Buy
+8,437
New +$415K 0.08% 499

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Fox Run Management's TARS Position: Q2 2026 in Review

Fox Run Management increased its Tarsus Pharmaceuticals (TARS) stake by 71% in Q2 2026, buying an estimated $212K and bringing the position to 8,004 shares worth $504K. The position accounts for 0.08% of the portfolio, ranked #471.

Fox Run Management first reported a position in TARS in Q3 2025 and has held it in 4 quarters since. The position peaked at $950K in Q4 2025. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Fox Run Management held 8,004 shares of Tarsus Pharmaceuticals worth $504K as of Q2 2026.
  • Fox Run Management bought 3,317 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $212K.
  • Tarsus Pharmaceuticals made up 0.08% of Fox Run Management's portfolio in Q2 2026, its #471 holding.
  • Fox Run Management first reported a position in Tarsus Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • Fox Run Management's Tarsus Pharmaceuticals position peaked at $950K in Q4 2025.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.